

High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Immune Cell Network

NCT06863974

Status	RECRUITING
Phase	Not Applicable
Sponsor	University Hospital, Angers
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (19)

- Age at inclusion between 1 and 18 years (included)
 - First demyelinating event at inclusion, such as ADEM encephalitis, optic neuritis (NORB) or myelitis, or a combination of these conditions.
 - Informed consent signed by patient's legal representative
 - MOGAD/ADEM group: presence of serum anti-MOG antibodies and diagnosis of ADEM (according to the International Pediatric Multiple Sclerosis Society Group (IPMSSG) criteria revised in 2013) at the first demyelinating attack.
 - Non-MOGAD/ADEM group: anti-MOG antibodies negative and diagnosis of ADEM at first demyelinating attack.
- ... and 14 more (see full listing online)

Locations (6 total)

CHU d'Angers, Angers, France
Univesity Hostipal of Brest, Brest, France
Univesity Hostipal of APHP, Le Kremlin-Bicêtre, France
... and 3 more locations

<https://clinicaltrials.gov/study/NCT06863974>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).